We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current LGND market cap is 2.2B. The company's latest EPS is USD 2.7601 and P/E is 42.31.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 26.37M | 34.99M | 28.1M | 30.98M | 41.53M |
| Operating Income | -1.98M | 3.08M | -3.36M | 2.99M | -19.1M |
| Net Income | 2.29M | -10.27M | 18.19M | 86.14M | -51.91M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 120.28M | 186.42M | 314.73M | 196.25M | 131.31M |
| Operating Income | -5.72M | 8.73M | 78.9M | 3.04M | 9.82M |
| Net Income | 629.3M | -2.99M | 57.14M | -33.36M | 52.15M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 758.11M | 769.23M | 787.22M | 913.87M | 866.41M |
| Total Liabilities | 93.21M | 101.33M | 86.3M | 107.35M | 91.21M |
| Total Equity | 664.89M | 667.9M | 700.91M | 806.52M | 775.2M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.49B | 1.36B | 1.3B | 762.67M | 787.22M |
| Total Liabilities | 727.68M | 652.76M | 476.43M | 165.18M | 86.3M |
| Total Equity | 767.23M | 709.53M | 821.16M | 597.49M | 700.91M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 33.87M | 41.51M | 49.58M | 18.73M | 32.05M |
| Investing | 18.11M | -1.4M | -11.68M | -3.78M | -58.53M |
| Financing | -68.53M | -65.26M | -59.95M | 12.18M | 21.67M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -29.34M | 54.59M | 78.8M | 137.85M | 49.58M |
| Investing | 466.92M | 231.65M | 30.52M | 163.62M | -11.68M |
| Financing | -485.17M | -310.55M | -137.76M | -275.99M | -59.95M |
| Market Cap | 2.2B |
| Price to Earnings Ratio | 42.31 |
| Price to Sales Ratio | 16.8 |
| Price to Cash Ratio | 96.13 |
| Price to Book Ratio | 3.15 |
| Dividend Yield | - |
| Shares Outstanding | 18.9M |
| Average Volume (1 week) | 120.11k |
| Average Volume (1 Month) | 148.03k |
| 52 Week Change | 100.95% |
| 52 Week High | 129.90 |
| 52 Week Low | 57.00 |
| Spread (Intraday) | 28.99 (21.33%) |
| Company Name | Ligand Pharmaceuticals Incorporated |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.ligand.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
